Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has demonstrated cardiovascular benefits in major trials involving over 17,000 participants. Beyond weight reduction, this medication class has shown protective effects on heart function and reduced major adverse cardiac events in certain patient populations. Understanding the actual cardiovascular impact requires separating clinical fact from social media speculation.
How Semaglutide Affects Cardiovascular Function
Semaglutide activates GLP-1 receptors throughout the body, including in the heart muscle and blood vessel lining. This activation triggers several mechanisms that may protect rather than harm cardiac tissue. The medication reduces inflammation, improves insulin sensitivity, and lowers blood pressure—all factors that benefit long-term heart health.
Weight loss itself carries significant cardiovascular advantages. Each kilogram of weight reduction correlates with improvements in blood pressure, cholesterol levels, and arterial flexibility. Patients using semaglutide typically lose 15-22% of body weight, which translates to measurable reductions in cardiac strain and metabolic stress on the heart.
Clinical Trial Evidence on Cardiac Safety
The SUSTAIN-6 trial, which followed 3,297 type 2 diabetes patients for two years, found that semaglutide reduced the risk of major adverse cardiovascular events by 26% compared to placebo. This landmark study established that GLP-1 therapy does not increase heart attack or stroke risk—it decreases these outcomes in high-risk populations.
The SELECT trial, published in 2023, examined cardiovascular outcomes in 17,604 overweight or obese individuals without diabetes. Results showed a 20% reduction in major adverse cardiovascular events among semaglutide users, regardless of baseline diabetes status. These findings demonstrate that cardiac protection extends beyond diabetic populations to general weight loss applications.
Side Effects That May Affect Heart Rate
Some patients report increased heart rate (tachycardia) when starting semaglutide, particularly during dose escalation phases. This typically occurs in 5-10% of users and often resolves within 4-8 weeks as the body adjusts. Increased heart rate during weight loss is partially a normal metabolic response to reduced caloric intake rather than a direct medication effect.
Dehydration, which occasionally accompanies gastrointestinal side effects like nausea, can contribute to temporary heart rate elevation. Maintaining adequate fluid intake and electrolyte balance minimizes this risk. Patients with pre-existing arrhythmias should discuss semaglutide use with their cardiologist, though absolute contraindications are rare.
Personalization Through Genetic Testing
PlexusDx offers the Precision Peptide Genetic Test, which examines individual variations in GLP-1 receptor pathways and cardiovascular risk genes. By analyzing variants such as GLP1R rs6923761 and MC4R rs17782313, this test identifies how your genetics influence medication response and metabolic trajectory. This information helps clinicians tailor therapy to your specific biology.
Genetic predispositions to heart disease, metabolic syndrome, or medication sensitivity inform safer, more effective treatment planning. Rather than a one-size-fits-all approach, personalized GLP-1 therapy considers your unique peptide pathways. PlexusDx's Precision Peptide Genetic Test ($99 add-on after first month) maps 14 metabolic pathways and 49 peptides to guide dosing and compound selection toward your cardiovascular health goals.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can semaglutide cause a heart attack?
Clinical evidence shows the opposite: major trials demonstrate that semaglutide reduces heart attack risk by approximately 20-26% compared to placebo. Serious cardiac events are less common in semaglutide users than in matched control groups, even when accounting for baseline health status.
Is semaglutide safe if I have existing heart disease?
Semaglutide is often beneficial for patients with established cardiovascular disease, as weight loss and improved metabolic markers reduce cardiac workload. However, individual risk assessment is essential. Always discuss your cardiac history with your healthcare provider before starting any GLP-1 therapy.
Why does my heart rate increase when I start semaglutide?
Mild heart rate elevation in early weeks often reflects metabolic adjustment rather than direct medication toxicity. Dehydration from nausea can also elevate heart rate. This effect typically diminishes within 4-8 weeks. If heart rate elevation persists or worsens, contact your provider immediately.
How much does PlexusDx compounded semaglutide cost?
PlexusDx Compounded Semaglutide Injection starts at $149 per month across all dose levels—your dose may need to go up, but your price won't. The medication comes from licensed 503A compounding pharmacies and is available in all 50 states without insurance or membership fees.
Can the Precision Peptide Genetic Test predict my cardiovascular response to GLP-1?
Yes. The Precision Peptide Genetic Test analyzes cardiovascular and metabolic pathway variants including GLP1R and MC4R genes to predict individual medication response, weight loss trajectory, and metabolic risk factors. This $99 add-on test (after first month of treatment) helps personalize your therapy for safer, more effective outcomes.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What to Eat on Zepbound When Not Hungry: A Comprehensive Guide
How to Reset Your Ozempic Pen: A Step-by-Step Guide